Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
doesn't it require only 50% of eligible votes. Mostly UK retail investors holding Longevity shares cannot vote anyway. I received reply from HL saying they cannot vote as they hold shares in CREST Depository Interests (CDIs) and not CREST directly. and big holders of $Loac (Chen, Oliveira etc.) will vote in favor so it should be passed without issue IMO.
I should have added, they also keep shorts in limit on 4D. shorts is in range of little over 0.5% to somewhat under 0.5%, so just feel like price management tactics.
One of the thought in my mind: Why would Citadel and Voleon interested in shorting small cap AIM company. They don't short any other small cap company. They can find dozens of bogus companies on AIM which have grown crazy. Voleon shorts only 4D and Metro Bank. Citadel shorts 4-5 other companies which are all multi billion market cap. It doesn't make any sense to short popular company with so much promising pipeline and share price of which has been battered and will list on Nasdaq in little over week. If let's say they think Microbiome sector won't work, then US listed companies like evelo, seres, kaleido etc. have phase 1/2 drugs for rarer diseases and are valued near or over billion $. Forte bioscience which has only one drug in pipeline recently entered phase 2 for inflammatory skin disease is valued double 4D market price. I think these shorts can be deliberate to spread panic, push down prices so bigger players can accumulate and then let it go. Like bigger players did spread panic and fear in name of inflation and bond yields to get retail investors out in fear and then brought low inflation report etc. getting growth stock shoot up again just before stimulus cheques which might sustain even bigger rallies (so who knows, perhaps bigger players might have done bit shorts and bogus fears in name of bond yields, bought at cheap price, closed short and now will enjoy bigger returns).
I am not sure if on LSE board of 4D there are many pumpers unlike some other stocks where ppl shamelessly lie. Here some people may have genuine high hope from 4D (including me :)). But yes everybody should listen to any detail coming out even if opposite to expectation (unless rampers/derampers). I personally think current 4D price is good one to invest as it is anyway very near to merger price now and any fund raise is also going to be at least merger price and if we get some solid investors, that will help price.
Welcome back Sangijuelas1. I miss your insights for past few days. Apparently you were only one of few guys (probably only one:) who had read SEC filings etc. in detail.
It must be citadel. Buy or sell, I think it bodes well for next few days. They increased shorts on 11th and 12th, so it reduced price those days but then when they bought back on 19th, it helped share price quite well. Now they increased short yesterday so despite much more buys price came down, today also they might have increased short. Though today there was lots of support around 1.35. They always increase decrease by 0.01%. So now they will buy back soon and with imminent nasdaq date news price may get extra boost. Even if no nasdaq news, citadel buying back itself will increase share price like it did on Friday
Hi Sangijuelas1, not sure why you decided this, but I would be interested in knowing your views. Thanks for asking question on vaccine on panel discussion, it was valuable information that came out from Duncan.
Hi guys, any recommendation for ISA account that allows transactions in US shares? Wants to transfer my Barclays ISA to the one where can buy US stocks. Thanks.
lol, colourful character. Forte bioscience is interesting, single live biotherapeutic drug on skin disease in pipeline in phase 1/2 and valuation is over $400 millions (by that standard 4D should be valued much higher). Citadel is co-owner with Oliveira.
I felt like Oliveira did provide few big sells today. some 50K, 30K etc. No way any big retail investor will sell in such big volume so near to nasdaq listing, so it could be to keep lid on price till nasdaq vote is done. Citadel's choice of short in 4D is also weird. They short mostly bigger companies in UK (mostly valuation over £1B), why would they choose small cap AIM company that too of quality of 4D which is also not over bought (low rsi). Anyway not many days left, once on nasdaq I believe we will get big re-rate with some held news released to market.
hmm, interesting find. Do you know if Oliveira (South ocean) was shareholder in Loac before or bought shares in Loac after this was finalized? I have seen them in shareholder list for long time at least since merger deal was made public.
Both employees from Merck mentioned in this report Gokul Swaminathan and Xue Liang do follow 4D on linked in. It is one of only couple of other companies they follow apart from Merck as interest.
Mansion, if your knowledge is that in US pre-revenue bio companies are not valued much, then stop wasting time here and stick to cineworld de-ramping. 4D has already good results out on their Oncology program, partnerships with Merck, lots of patents and platform programs. I believe what 4D will do is once Nasdaq listing is done, will release phase 2b data on MRX518-Ketruda combo raise funds at much higher rate and then have other releases in second half (Pancreatic cancer, Asthma). We could also hear on IBS phase 3 initiation in partnership or progress on vaccine program with Merck and company will be valued much higher. I guess Merck team must have much more knowledge than you and me to partner with 4D in vaccine development, MRX0518 and buying 6% of company shares.
Don't know much about spread betting. What you mean by platforms are 'closing positions only'? When citadel involved, cannot rule out collusion of platforms like today Citadel influenced platforms like robinhood etc. allowing only selling and no buying of short squeezed shares. I won't be surprised if in UK markets also citadel has collusion with MMs, platforms and steal money from retail shareholders. Trade patterns in 4D is very weird, the way AT sells of rounded figures get raided (feels like stop losses being raided, but why it happens only in 4D and not other AIM shares e.g. avct where all trades are OB. Is it only 4D shareholders have stop losses setup, which is hard to believe). Fall in 4D share price on 7th and thereafter subdued growth where all sundries and bogus shares on AIM grew crazy, many even multi bag, 4D was momentarily allowed to go to 1.30 and then dragged back despite being much better quality and undervalued.
rsi is 44 which was when sp was 90p. So it is good opportunity to buy as after rsi of 44 we got 50% rise to over £1.30 recently.
4D needs bit of volume (some news from company would be nice). Most of holders now should be long term sticky holders (hopefully Norwood has finished his shares). There was volume from Dec end till first couple of weeks of Jan, but that period Norwood was selling all his shares. I wish 4D gets some more popularity and pressure on buy side sending Citadel packing away. Like Citadel and other shorter has now come to support their fellow shorter Melvin which is getting burnt on $gme (Gamestop) short squeeze with reddit users promoting, hopefully here also retailers start piling up buying on 4D would get us big speedy rise.
Don't worry about me Mansion, you do better deramping or won't be paid salary. I think we don't need to check shorting website, just your appearance should tell Citadel was back shorting last Friday. I think once they are gone back from 0.49% to 0, you will also disappear like last few weeks.
forgot to mention luck part. Company's PR before SITC was quite good with few quality tweets, publishing in media etc. but we got SITC rns (monotherapy and combo) out immediately after pfizer vaccine news (which caused all small cap pharma plummet). PR has been bit low profile after SITC, which makes you feel either company is not allowed to publish any material news before nasdaq listing or they want to do all PR once nasdaq listing is done. Anyway not many days/weeks left now so will keep patient to reap the rewards.
Luck hasn't been on our side for last few months. After 7th Oct with shorting and selling stock price plummeted. Since then shorters, bit selling from Oliveira group did always pull back price whenever there was bit of spike. One of major problem has been complete selling by Norwood (opportunity for many to get cheap shares) of few million shares. Last of rns in Dec where he was below 3% he still had 3 million shares which I believe mostly must be sold now the way bit chunk of shares were being sold for last few weeks. If Norwood took a rest 4D price would have easily gone to more than 1.60-1.80 as there was very good buying pressure for past 4 weeks. Since start of this week buying has come down (selling too but still some sells appearing). At the moment most of trades in 4D are algo trades (could be stop losses being hit) with some chunks of sells but nothing like past few weeks when we had daily volume of more than £1 million buying and bit below that selling. Some stocks like 4D are always having lots of AT (automatic trades) where as some have hardly one (e.g. avct). Not sure if company is barred from publishing any trial data till Nasdaq listing, but I feel once sec review is done and we get news of share holder meeting for vote, it should give very good boost. Then Nasdaq listing and company would surely come up with good trial results and that would take this share much higher (probably bags). Ideally it would be good if 4D publish something good result before Nasdaq listing to get some publicity, nasdaq listing and then again good results, but anyway Nasdaq listing itself will give major reward because our counterpart $loac can run crazy (like one day it went to $19 with 50%+ rise) and that will have effect on 4D price as well IMHO.
Tiziana (Tils) published rns for these (participation and pre-recorded presentation) on 11th afternoon and that boost share price on 11th and 12th. I do like approach of 4D which doesn't publish rns on unimportant events, though I wish they do it in such booming time in market. These days slightest good rns is giving north of 15% boost to any share.